Company to Ring Opening Bell June 14 to Bring Awareness to Addiction
Treatment;
Company Will Maintain Premium Listing on
London Stock Exchange
RICHMOND, Va., June 12,
2023 /PRNewswire/ -- Indivior PLC (LSE: INDV), a
global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders
(SUD) and serious mental illnesses, today announces that the U.S.
Securities & Exchange Commission (SEC) declared its
registration statement on Form 20-F effective on June 9. Trading in Indivior ordinary shares on
the Nasdaq Global Select Market will commence at U.S. market open
today.
Indivior will retain its premium listing on the London Stock
Exchange and inclusion in the FTSE 250 index, and its ordinary
shares will trade on both exchanges under the ticker symbol "INDV."
The Company also notes that no shares are being offered as part of
the additional U.S. listing.
"The additional U.S. listing of Indivior shares is an important
milestone," said Mark Crossley, CEO.
"We believe it will bring additional exposure to both Indivior and
the disease space in the U.S., which is our largest opportunity
market. Over time, we expect it will facilitate increased ownership
by additional U.S.-based biopharma investors. We also are mindful
of the significant unmet need for opioid use disorder
treatment in the U.S., and are hopeful our U.S. listing will help
raise awareness of the opioid epidemic."
Crossley, along with a number of patients and their families,
will ring the Opening Bell at the Nasdaq MarketSite in Times Square
on June 14 to celebrate the company's
Nasdaq listing and raise awareness of the millions of people
affected by substance use disorders and mental health challenges.
Members of the Indivior executive team and employees also will be
in attendance.
"When we ring the Nasdaq opening bell, we hope to bring focus to
our patients and the immense challenges they face," said Crossley.
"Addiction is often misunderstood as a personal moral failing, but
the reality is that it is a disease that requires medical treatment
like any other chronic illness. At Indivior, we want to change how
substance use disorders, mental illness, and opioid overdose are
viewed and treated. We are committed to ending the stigma of
addiction and helping our patients on their journey to
recovery."
Indivior launched a new patient-focused campaign to complement
the company's Nasdaq listing and the bell ringing event. The
patients in attendance at the bell ringing are featured in the ad
campaign, which humanizes addiction and shows that recovery is
possible.
The patient-focused campaign is running across digital
platforms, print, newsletters and outside advertising in Times
Square. To learn more, visit indivior.com/en/investors.
Important Cautionary Note Regarding Forward-Looking
Statements
This announcement contains certain statements that are
forward-looking. Forward-looking statements include, among
other things, statements regarding the timing of our planned
additional U.S. stock exchange listing, expectations
regarding future index inclusion, and other statements
containing the words "believe," "anticipate," "plan," "expect,"
"intend," "estimate," "forecast," "strategy," "target," "guidance,"
"outlook," "potential," "project," "priority," "may," "will,"
"should," "would," "could," "can," "outlook," "guidance," the
negatives thereof, and variations thereon and similar expressions.
By their nature, forward-looking statements involve risks and
uncertainties as they relate to events or circumstances that may or
may not occur in the future.
Actual results may differ materially from those expressed or
implied in such statements because they relate to future events.
Various factors may cause differences between Indivior's
expectations and actual results, including, among others, the
material risks described in the most recent Indivior PLC Annual
Report and in subsequent releases; our ability to commercialize and
market acceptance of new products; the substantial litigation and
ongoing investigations to which we are or may become a party; our
reliance on third parties to manufacture commercial supplies of
most of our products, conduct our clinical trials and at times to
collaborate on products in our pipeline; our ability to comply with
legal and regulatory settlements, healthcare laws and regulations,
requirements imposed by regulatory agencies and payment and
reporting obligations under government pricing programs; risks
related to the manufacture and distribution of our products, some
of which are controlled substances; market acceptance of our
products as well as our ability to commercialize our products and
compete with other market participants; the uncertainties related
to the development of new products, including through acquisitions,
and the related regulatory approval process; our dependence on a
small number of significant customers; our ability to retain key
personnel or attract new personnel; our dependence on third-party
payors for the reimbursement of our products and the increasing
focus on pricing and competition in our industry; unintended side
effects caused by the clinical study or commercial use of our
products; our use of hazardous materials in our manufacturing
facilities; our import, manufacturing and distribution of
controlled substances; our ability to successfully execute
acquisitions, partnerships, joint ventures, dispositions or other
strategic acquisitions; our ability to protect our intellectual
property rights and the substantial cost of litigation or other
proceedings related to intellectual property rights; the risks
related to product liability claims or product recalls; the
significant amount of laws and regulations that we are subject to,
including due to the international nature of our business;
macroeconomic trends and other global developments such as the
COVID-19 pandemic; the terms of our debt instruments, changes in
our credit ratings and our ability to service our indebtedness and
other obligations as they come due; changes in applicable tax rate
or tax rules, regulations or interpretations; and our ability to
realize our deferred tax assets.
Forward-looking statements speak only as of the date that they
are made and should be regarded solely as our current plans,
estimates and beliefs. Except as required by law, we do not
undertake and specifically decline any obligation to update,
republish or revise forward-looking statements to reflect future
events or circumstances or to reflect the occurrences of
unanticipated events.
About Indivior
Indivior is a global pharmaceutical company working to help
change patients' lives by developing medicines to treat substance
use disorders (SUD) and serious mental illnesses. Our vision is
that all patients around the world will have access to
evidence-based treatment for the chronic conditions and
co-occurring disorders of substance use disorder (SUD). Indivior is
dedicated to transforming SUD from a global human crisis to a
recognized and treated chronic disease. Building on its global
portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category
and potentially address other chronic conditions and co-occurring
disorders of SUD, including alcohol use disorder and cannabis use
disorder. Headquartered in the United
States in Richmond, VA, Indivior employs more than 1,000
individuals globally and its portfolio of products is available in
39 countries worldwide. Visit www.indivior.com to learn
more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/indivior-to-commence-trading-on-nasdaq-301847965.html
SOURCE Indivior PLC